Evidence map›Paper›PMID 29232184›Full record

ArticleRadiology2018

Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer.

Emily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, Scott Genshaft, Fereidoun Abtin, Antonio Gutierrez, Hyun J Kim, Alice Li, Carlos Adame, Ashkan Jalalian and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Article
  6. Article
  7. Review
  8. Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  9. Article
  10. Observational
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Emily B TsaiFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Kelsey PomykalaFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Kathleen RuchalskiFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Scott GenshaftFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Fereidoun AbtinFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Antonio GutierrezFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Hyun J KimFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Alice LiFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Carlos AdameFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Ashkan JalalianFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Brian WolfFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Edward B GaronFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Jonathan W GoldmanFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.
Robert SuhFrom the Department of Radiological Sciences (E.B.T., K.P., K.R., S.G., F.A., A.G., H.J.K., R.S.) and Department of Medicine, Division of Hematology/Oncology (A.L., C.A., A.J., B.W., E.B.G., J.W.G.), University of California Los Angeles, Los Angeles, Calif.

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
A model for predicting response to PD-1 inhibitors in NSCLCR01CA208403 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GARON, EDWARD B · 2017 to 2021
$3.2M
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA208403
6 · The paper itself

Abstract

Purpose To determine feasibility and safety of biopsy and repeat biopsy for assessment of programmed cell death ligand-1 (PD-L1) status. Materials and Methods This retrospective analysis reviewed 101 patients who underwent transthoracic core needle biopsy for the KEYNOTE-001 (MK-3475) clinical trial of pembrolizumab, an antiprogrammed cell death-1 therapy for non-small cell lung cancer, from May 2012 to September 2014. Sixty-one male patients (mean age, 66.1 years; range 36-83 years) and 40 female patients (mean age, 66.8 years; age range, 36-90 years) were included. Data collected included population characteristics, treatment history, target location, size, and depth from pleura. Adequacy of the tissue sample for diagnostic testing and rates of biopsy-related complications were assessed. Statistical analysis was performed by using univariate and multivariate generalized linear models to determine significant risk factors for biopsy complications. Results A total of 110 intrathoracic biopsies were performed, and 101 (91.8%) were performed as repeat biopsies subsequent to a previous percutaneous or bronchoscopic biopsy or previous surgical biopsy or resection. More than 84.5% (93 of 110) of biopsies were performed in patients who had undergone previous local or systemic therapy. Specimens were adequate for evaluation of PD-L1 expression in 96.4% of biopsies. Procedure-related complications occurred in 28 biopsies (25.4%); pneumothorax was most common (22.7%). Overall mean number of core needle biopsy samples obtained was 7.9 samples. Conclusion Image-guided transthoracic core needle biopsy is an effective method for obtaining tissue for PD-L1 expression analysis.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorBiopsy, Large-Core NeedleCarcinoma, Non-Small-Cell LungFeasibility StudiesFemaleHumansImage-Guided BiopsyImmunotherapyLungLung NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, Tumorpembrolizumab

Identifiers

PMID29232184
PMCPMC6276060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.